<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parry, Nicola</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Bhatt, Deepak L.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Perspectives on Secondary Prevention of Atherothrombotic Events</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">32-33</style></pages><abstract><style  face="normal" font="default" size="100%">The risk of recurrent cardiovascular events in patients with a history of atherothrombosis remains high, at about 10% annually, despite the use of guideline-based, disease-modifying therapies. This article discusses strategies to address residual risk through secondary prevention in patients following an acute coronary syndrome, oral antiplatelet agents, and polyvascular disease.</style></abstract><number><style face="normal" font="default" size="100%">30</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>